SwingTrade Member Forum

[Rawnoc]

REPR is setting up to be a huge home run IMO. Here's why:

(1) On May 20, 2011 REPR received their long anticipated FDA approval for the marketing of their new needle set. It is expected that this approval will lead to a significant increase in sales and REPR is underdoing significant manufacturing expansion and stockpiling of inventory in anticipation of this. Sales begin with the next reported quarterly report.

(2) Freedom60 Sales (their main product) are continuing to explode led by an increasing recurring revenue stream as Hizentra and other drugs -- patients tend to be patients for life who require REPR's tubing sets every month which run over $325 per year per patient for life. Hizentra sales continue to explode and the maker of Hizentra continues to promote REPR's Freedom60 device and tubing sets. 10Q forecasts further increases as a result of Hizentra drug approval last year and the Freedom60 now used for other drugs as well.

(3) REPR's Freedom60 device is the only one of its kind approved by Medicare.

(4) Rock solid balance sheet with a large and growing cash position, very little debt, and zero need for dilution.

(5) REPR recently had some insider buying in the open market.